novartis glp-1 Readout Newsletter: Sage, Sanofi, Novartis, Novovax news GLP-1 Agonists: A Comprehensive Overview

While initial safety concerns surrounding pancreatic and thyroid cancers led to regulatory scrutiny of incretin-based therapies, this meta-analysis of 93 RCTs shows no significant increase in pancreatic cancer risk

Investigators analyzed 132 randomized controlled trials, enrolling 48,209 adults with overweight or obesity

Like its injectable counterpart, it also carries approval to reduce the risk of major adverse cardiovascular events (MACE), including cardiovascular death, heart attack, and stroke, in adults with established heart disease and obesity or overweight

Decisions about continuation, changes, or discontinuation, which Willow does not override

With tirzepatide, lower doses reduce signaling through both the GLP-1 and GIP pathways at the same time